sever
acut
respiratori
syndrom
sar
emerg
infecti
diseas
caus
novel
sarsassoci
coronaviru
sarscov
clinic
characterist
high
fever
rapidli
progress
diffus
pneumon
respiratori
distress
highli
infecti
intim
contact
direct
contact
infecti
bodi
fluid
outbreak
within
commun
hospit
report
develop
rapid
reliabl
diagnost
tool
urgent
need
develop
immunoglobulin
g
igg
enzymelink
immunosorb
assay
elisa
use
whole
viru
antigen
sarscov
eightysix
serum
sampl
collect
patient
hospit
caus
examin
determin
cutoff
od
valu
cutoff
od
valu
defin
calcul
mean
od
valu
sera
plu
standard
deviat
determin
sensit
specif
elisa
posit
sera
neg
sera
test
sensit
specif
result
suggest
igg
elisa
use
whole
viru
antigen
sarscov
high
sensit
specif
detect
sar
igg
antibodi
igg
elisa
power
tool
serodiagnosi
sar
sever
acut
respiratori
syndrom
sar
emerg
infecti
diseas
clinic
characterist
fever
dri
cough
myalgia
dyspnea
lymphopenia
abnorm
chest
radiograph
result
signific
proport
patient
sar
fulmin
cours
character
high
fever
rapidli
progress
diffus
pneumon
respiratori
failur
case
sar
first
report
guandong
provinc
southern
china
novemb
follow
report
vietnam
hong
kong
singapor
canada
taiwan
septemb
person
report
infect
patient
die
sar
case
fatal
ratio
reach
respons
pathogen
sar
newli
discov
sarsassoci
coronaviru
sarscov
viru
transmit
contact
respiratori
droplet
fomit
respiratori
secret
viru
highli
contagi
abl
caus
outbreak
within
commun
hospit
delay
diagnosi
failur
isol
sar
patient
hospit
lead
transmiss
viru
healthcar
worker
patient
howev
difficult
distinguish
sarscov
infect
acut
viral
respiratori
diseas
influenza
base
clinic
present
current
laboratori
diagnosi
sarscov
infect
achiev
isol
viru
cell
cultur
detect
viral
nucleic
acid
reversetranscriptas
polymeras
chain
reaction
rtpcr
method
either
timeconsum
inadequ
sensit
reason
develop
rapid
reliabl
diagnost
tool
urgent
need
studi
describ
sensit
specif
elisa
detect
sarscov
igg
use
routin
diagnosi
largescal
popul
surveil
prepar
identif
wholeviru
antigen
elisa
sarscov
isol
propag
vero
cell
mem
medium
jrh
lenexa
usa
supplement
fetal
calf
serum
fc
virus
harvest
cultur
supernat
h
inocul
cell
show
cytopathogen
effect
centrifug
g
min
discard
pellet
contain
exfoli
cell
supernat
heat
h
inactiv
sarscov
filter
lm
pore
sartoriu
goettingen
germani
dispos
bacteria
supernat
suspend
polyethylen
glycol
sigma
st
loui
mo
usa
centrifug
g
h
pellet
contain
virus
resuspend
pb
buffer
purifi
sucros
gradient
centrifug
g
h
viral
fraction
wash
pb
centrifug
g
h
pellet
contain
purifi
whole
cell
viral
antigen
concentr
purifi
viral
protein
measur
use
biorad
protein
assay
kit
biorad
hercul
ca
usa
purifi
whole
viru
antigen
subject
polyacrylamid
electrophoresi
stain
coomassi
blue
western
blot
analysi
use
sar
patient
sera
understand
protein
contain
prepar
purifi
viral
protein
lg
dilut
mm
na
co
ph
use
coat
well
microtit
plate
overnight
plate
block
llwell
block
buffer
fc
superblock
pierc
rockford
il
usa
room
temperatur
h
sera
pretreat
min
dilut
block
buffer
two
hundr
microlit
dilut
sera
ad
well
incub
room
temperatur
min
plate
wash
five
time
wash
buffer
contain
pb
tween
thereaft
goat
antihuman
igg
antibodi
chemicon
temecula
ca
usa
dilut
block
buffer
ad
well
incub
room
temperatur
min
plate
wash
five
time
wash
buffer
specif
antisarscov
igg
detect
ad
tmb
kpl
gaithersburg
md
usa
absorb
measur
nm
ad
h
solut
test
sera
collect
patient
visit
nation
taiwan
univers
hospit
diseas
sar
determin
cutoff
od
valu
igg
elisa
none
patient
whose
sera
use
cutoff
valu
determin
prior
contact
histori
sar
patient
sera
confirm
seroneg
sarscov
immunofluoresc
assay
ifa
dilut
mean
od
valu
sera
plu
standard
deviat
calcul
cutoff
od
valu
igg
elisa
determin
sensit
specif
elisa
true
posit
true
neg
control
sera
defin
test
true
posit
control
sera
collect
patient
sar
test
posit
ifa
clinic
sar
patient
diagnos
accord
criteria
true
neg
control
sera
collect
sar
first
report
test
neg
ifa
data
analyz
spss
statist
packag
version
leadtool
chicago
il
usa
spearman
rank
order
correl
use
examin
correl
od
valu
time
patient
sera
collect
purifi
sar
cov
antigen
underw
sd
page
stain
coomassi
blue
well
patient
sera
figur
sever
antigen
identifi
coomassi
blue
stain
whole
viru
prepar
includ
four
structur
protein
includ
spike
envelop
e
membran
nucleocapsid
n
result
western
blot
major
antigen
recogn
patient
sera
kda
n
protein
eightysix
sera
collect
patient
visit
nation
taiwan
univers
hospit
caus
test
cutoff
valu
determin
includ
respiratori
tract
infect
nonrespiratori
infect
noninfecti
diseas
sera
seroneg
test
ifa
mean
od
valu
standard
deviat
calcul
respect
thu
cutoff
valu
defin
sera
sensit
fiftysix
serum
sampl
collect
serial
sar
patient
test
ifa
elisa
three
male
femal
age
rang
year
old
patient
fever
pneumonia
april
may
among
eight
healthcar
worker
two
hospit
nosocomi
sar
outbreak
six
visit
admit
two
hospit
outbreak
period
three
household
contact
sar
patient
detect
sarscov
nucleic
acid
rtpcr
plasma
throat
swab
stool
sampl
done
patient
patient
posit
result
sera
posit
igg
antisar
cov
use
ifa
collect
day
median
day
fever
onset
fiftyfour
sera
reactiv
igg
elisa
od
valu
higher
defin
cutoff
od
valu
posit
sera
rang
mean
od
valu
figur
fortynin
sera
od
valu
higher
two
fals
neg
sera
collect
day
fever
onset
respect
five
sera
od
valu
collect
day
onset
fever
respect
od
valu
tend
higher
sera
collect
later
diseas
cours
p
figur
sensit
sarscov
igg
elisa
two
hundr
four
sera
collect
sar
first
report
consid
true
neg
control
sera
collect
healthi
children
teenag
differ
age
group
children
age
less
year
old
year
old
year
old
year
old
none
sera
igg
antibodi
sarscov
test
ifa
sera
seroneg
elisa
mean
od
figur
two
hundr
one
sera
od
valu
less
specif
sarscov
igg
elisa
studi
develop
sarscov
igg
elisa
use
whole
sarscov
antigen
igg
two
key
step
develop
good
elisa
detect
antibodi
viral
antigen
first
step
defin
appropri
cutoff
valu
posit
read
second
step
involv
reduc
background
nois
set
cutoff
valu
mean
od
valu
plu
standard
deviat
test
neg
serum
sampl
deriv
cutoff
valu
abl
accur
differenti
seroposit
seroneg
serum
sampl
high
sensit
specif
initi
use
skim
milkbas
block
buffer
suggest
sever
protocol
howev
background
od
valu
unaccept
high
data
shown
therefor
tri
new
block
buffer
contain
fetal
calf
serum
superblock
also
increas
concentr
tween
wash
buffer
modif
success
reduc
nonspecif
reaction
sarscov
igg
elisa
fetal
calf
serum
use
block
buffer
protocol
one
previou
studi
also
show
block
buffer
contain
fetal
calf
serum
abl
reduc
background
nois
present
protocol
use
skim
milkbas
block
buffer
studi
whole
sarscov
use
antigen
specif
elisa
compar
recombin
viral
protein
antigen
advantag
use
whole
viru
antigen
speed
simplic
prepar
without
need
recombinantdna
techniqu
express
purif
viral
protein
recombin
protein
antigenbas
elisa
found
low
specif
one
elisa
enteroviru
antibodi
detect
furthermor
infect
patient
usual
mount
variabl
antibodi
respons
sever
antigen
viru
use
multipl
viru
antigen
theoret
could
sensit
determin
antibodi
respons
compar
assay
use
singl
viral
antigen
safeti
issu
alway
concern
develop
whole
virusbas
elisa
addit
oper
level
biosafeti
laboratori
protocol
use
prolong
heat
min
inactiv
viru
necessari
evid
suggest
heat
less
min
ineffect
steril
sar
cov
sr
shih
person
commun
posit
sera
studi
od
valu
higher
sera
od
valu
lower
includ
two
fals
neg
sera
six
collect
later
day
fever
onset
thu
believ
low
od
valu
serum
sampl
obtain
within
week
fever
onset
interpret
caution
serial
sampl
recommend
establish
diagnosi
neg
control
sera
collect
children
teenag
year
old
subject
young
supposedli
experienc
frequent
viru
infect
none
sera
reactiv
thu
suggest
crossreact
preval
virus
among
children
teenag
major
concern
sarscov
igg
elisa
conclus
success
develop
igg
elisa
use
whole
sarscov
antigen
protocol
quick
simpl
high
sensit
specif
detect
sar
igg
antibodi
igg
elisa
power
tool
rapid
serodiagnosi
sar
seroepidemiolog
survey
